Refine
Has Fulltext
- yes (32) (remove)
Is part of the Bibliography
- yes (32)
Year of publication
Document Type
- Journal article (31)
- Habilitation (1)
Keywords
- Medizin (3)
- liraglutide (3)
- obesity (3)
- Fn14 (2)
- MIZ1 (2)
- MYC (2)
- NFκB (2)
- Roux-en-Y gastric bypass surgery (2)
- TWEAK (2)
- agonistic antibodies (2)
- cell death (2)
- chemotherapy (2)
- colorectal cancer (2)
- gastric bypass (2)
- inflammation (2)
- peptide tyrosine tyrosine (PYY) (2)
- 5-fluorouracil (1)
- AAA (1)
- Barrett-Ösophagus (1)
- CRC (1)
- CX5461 (1)
- Caco2 cells (1)
- Chirurgie (1)
- Claudin2 (1)
- Dsg2 (1)
- FWGE (1)
- FcγR (1)
- GLP-1 (1)
- Germany (1)
- HUWE1 (1)
- Hesse (1)
- Krebs (1)
- Lebertransplantat-Spontantoleranz (1)
- MAPK signaling cascades (1)
- MHC molecules (1)
- NAFLD (1)
- NASH (1)
- Neolithic agriculture (1)
- PI-3-kinase (1)
- PYY3-36 (1)
- RNAPOL1 (1)
- RT-qPCT (1)
- RYGB (1)
- Regulator T-Lymphozyten (1)
- TKTL1 (1)
- TNF (1)
- TNF receptor superfamily (1)
- Transplantation (1)
- Y-gastric bypass (1)
- Zucker fatty fa/fa rats (1)
- adipose-derived stromal/stem cells (ASCs) (1)
- allogene MHC-Peptide (1)
- anti-tumor effects (1)
- antigen-specific therapy (1)
- antigenspezifische Therapie (1)
- autophagy (1)
- bariatric surgery (1)
- benzoquinone (1)
- biliopancreatic diversion (1)
- biological models (1)
- body weight (1)
- breast cancer (1)
- caco-2 cells (1)
- cadaver multiorgan preservation (1)
- cancer (1)
- cancer cell lines (1)
- cancer cells (1)
- carcinomas (1)
- chemistry (1)
- colon (1)
- colorectal carcinoma (1)
- cotransporter SGLT1 (1)
- cytostatic (1)
- cytotoxicity (1)
- desmosome (1)
- digestive system (1)
- drug discovery (1)
- duodenal jejunal bypass (1)
- energy homeostasis (1)
- enteroids (1)
- experimental archaeology (1)
- extracorporeal membrane oxygenation (1)
- fatty liver (1)
- food intake (1)
- glucagon like peptide-1 (1)
- glucose homeostasis (1)
- glucose starvation (1)
- gut barrier (1)
- gut hormones (1)
- histologic diversity (1)
- hypothalamic gene expression (1)
- hypoxia (1)
- immunohistochemistry (1)
- implementation (1)
- inflammatory bowel disease (1)
- inflammatory cell model (1)
- intestinal barrier (1)
- intestinal epithelial barrier (1)
- intestinal glucose (1)
- intestinal organoids (1)
- ionizing radiation (1)
- ischemia (1)
- ischemic-stroke (1)
- ketogenic dients (1)
- ketogenic diet (1)
- ketone bodies (1)
- leptin system (1)
- metabolic profile (1)
- metastasis (1)
- miRNA expression (1)
- mice (1)
- mild hypothermia (1)
- oxaliplatin (1)
- pathway analysis (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- pharmacology (1)
- popliteal aneurysm (1)
- post-mortem heart recovery (1)
- protein expression (1)
- quality indicators (1)
- quality of health care (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- reactive oxygen species (1)
- regenerative medicine (1)
- regulatory T cells (1)
- rehabilitation (1)
- ribosome (1)
- rygb (1)
- seahorse (1)
- secretion (1)
- slash-and-burn (1)
- small interferring RNA (1)
- spontaneous liver allograft tolerance (1)
- stroke register (1)
- stroke unit care (1)
- study-group ADSR (1)
- temperate Europe (1)
- tight junction (1)
- translational research (1)
- transplantation (1)
- treatment (1)
- trophic factors (1)
- ubiquitination (1)
- β-Hydroxybutyrate (1)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (27)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Frauenklinik und Poliklinik (5)
- Institut für Anatomie und Zellbiologie (4)
- Medizinische Klinik und Poliklinik I (4)
- Pathologisches Institut (4)
- Medizinische Klinik und Poliklinik II (3)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Molekulare Infektionsbiologie (2)
Sonstige beteiligte Institutionen
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
(2023)
Fibroblast growth factor (FGF)-inducible 14 (Fn14) activates the classical and alternative NFκB (nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells) signaling pathway but also enhances tumor necrosis factor (TNF)-induced cell death. Fn14 expression is upregulated in non-hematopoietic cells during tissue injury and is also often highly expressed in solid cancers. In view of the latter, there were and are considerable preclinical efforts to target Fn14 for tumor therapy, either by exploiting Fn14 as a target for antibodies with cytotoxic activity (e.g. antibody-dependent cellular cytotoxicity (ADCC)-inducing IgG variants, antibody drug conjugates) or by blocking antibodies with the aim to interfere with protumoral Fn14 activities. Noteworthy, there are yet no attempts to target Fn14 with agonistic Fc effector function silenced antibodies to unleash the proinflammatory and cell death-enhancing activities of this receptor for tumor therapy. This is certainly not at least due to the fact that anti-Fn14 antibodies only act as effective agonists when they are presented bound to Fcγ receptors (FcγR). Thus, there are so far no antibodies that robustly and selectively engage Fn14 signaling without triggering unwanted FcγR-mediated activities. In this study, we investigated a panel of variants of the anti-Fn14 antibody 18D1 of different valencies and domain architectures with respect to their inherent FcγR-independent ability to trigger Fn14-associated signaling pathways. In contrast to conventional 18D1, the majority of 18D1 antibody variants with four or more Fn14 binding sites displayed a strong ability to trigger the alternative NFκB pathway and to enhance TNF-induced cell death and therefore resemble in their activity soluble (TNF)-like weak inducer of apoptosis (TWEAK), one form of the natural occurring ligand of Fn14. Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK.
Loss of intestinal epithelial barrier function is a hallmark in digestive tract inflammation. The detailed mechanisms remain unclear due to the lack of suitable cell-based models in barrier research. Here we performed a detailed functional characterization of human intestinal organoid cultures under different conditions with the aim to suggest an optimized ex-vivo model to further analyse inflammation-induced intestinal epithelial barrier dysfunction. Differentiated Caco2 cells as a traditional model for intestinal epithelial barrier research displayed mature barrier functions which were reduced after challenge with cytomix (TNFα, IFN-γ, IL-1ß) to mimic inflammatory conditions. Human intestinal organoids grown in culture medium were highly proliferative, displayed high levels of LGR5 with overall low rates of intercellular adhesion and immature barrier function resembling conditions usually found in intestinal crypts. WNT-depletion resulted in the differentiation of intestinal organoids with reduced LGR5 levels and upregulation of markers representing the presence of all cell types present along the crypt-villus axis. This was paralleled by barrier maturation with junctional proteins regularly distributed at the cell borders. Application of cytomix in immature human intestinal organoid cultures resulted in reduced barrier function that was accompanied with cell fragmentation, cell death and overall loss of junctional proteins, demonstrating a high susceptibility of the organoid culture to inflammatory stimuli. In differentiated organoid cultures, cytomix induced a hierarchical sequence of changes beginning with loss of cell adhesion, redistribution of junctional proteins from the cell border, protein degradation which was accompanied by loss of epithelial barrier function. Cell viability was observed to decrease with time but was preserved when initial barrier changes were evident. In summary, differentiated intestinal organoid cultures represent an optimized human ex-vivo model which allows a comprehensive reflection to the situation observed in patients with intestinal inflammation. Our data suggest a hierarchical sequence of inflammation-induced intestinal barrier dysfunction starting with loss of intercellular adhesion, followed by redistribution and loss of junctional proteins resulting in reduced barrier function with consecutive epithelial death.